Feasibility and Acceptability of Hair- and Dried Blood Spot-Derived ARV Biomarkers as Objective Measures of Treatment Adherence in South Africa

Reuben Robbins, Hetta Gouse, Patricia Warne, Yoliswa Mtingeni, Michelle Henry, Javier Lopez Rios, Claude Mellins, John Joska, Robert Remien

HIV Center, NYS Psychiatric Institute and Columbia University; University of Cape Town



INTRODUCTION

- ART adherence research and clinical care hampered by lack of objective measure of medication adherence
 - Current strategies: unannounced pill counts, electronic monitoring devices, pharmacy records
 - **Do not** measure actual ingestion
 - Newer strategies: drug levels in hair and blood
 - Do measure ingestion over the course of approx. several weeks



MONITORING ARVs IN BLOOD AND HAIR

- Two important aspects of objective measures of ART adherence should be that they
 - impose minimal burden on patients/research participants and on healthcare systems
 - be usable in a variety of settings (e.g., clinic, home)

Dried blood spot (DBS) and hair samples are

- Minimally invasive (DBS) or non-invasive (hair)
- Usually considered minimal risk
- Inexpensive to collect (i.e., materials and personnel)
- Suitable for repeated sampling/ongoing monitoring



RESEARCH QUESTIONS

- How acceptable and feasible to patients are collecting hair and blood samples?
 - How burdensome/painful are giving regular samples?
 - Could collection occur at the clinic and at home?
 - Could patients collect DBS by themselves?
 - Are there concerns about the use of one's blood and hair samples?



SETTING



PARENT STUDY

- Sub-sample of participants in the Masivukeni ART adherence RCT
 - NIMH-funded RCT of a laptop-based, multimedia and interactive ART adherence intervention
 - HIV+ adults initiating ART in Cape Town health clinics
 - Monitored via Wisepill



PILOT METHODS

Eligibility

- Enrolled in Masivukeni
- On first line ART regimen (e.g., Atroiza or Odimune containing tenofovir) for 1-2 months
- Attend 5 study visits, one month apart
- Provide hair and blood samples at each visit



PILOT METHODS

At each monthly visit, nurse collected
Finger-stick for DBS sampling
Hoir complet (opprov. 100 strends)

- Hair sample (approx. 100 strands)
- Brief survey
- R300 (≈\$30) incentive for each study visit



PROCEDURE



RESULTS: PARTICIPANT CHARACTERISTICS

- 30 participants enrolled
- Demographics
 - 90% women, 100% Black African
 - Mean age: 30 years (SD=5.25)
- 28 participants completed all 5 study visits; 2 completed 4 visits
 - 148 total finger-stick and hair collection samples
 - 148 completed surveys



RESULTS: PAIN FROM DBS





RESULTS: WILLINGNESS TO DO DBS REGULARLY





RESULTS: WILLING TO TO DBS AT HOME





RESULTS: CONFIDENCE DOING DBS BY SELF





RESULTS: DBS ACCEPTABILITY AND FEASIBILITY

- What was it like for you to have your finger pricked and give blood samples today?
 - Most responses: "a little painful", "slightly sore", "wasn't too bad", "wasn't painful"
- Throughout all visits, ≥ 90% of participants reported willingness to have a health worker come to their home to do finger-stick.



RESULTS: WILLINGNESS TO GIVE HAIR REGULARLY





RESULTS: HAIR ACCEPTABILITY AND FEASIBILITY

- No one at any point reported experiencing any pain from the hair collection procedure
- What was it like for you to give a hair sample today?
 - Most responses: "fine," and "okay". One participant responded "a bit stressful," another, "I'm just worried my hair isn't growing quickly enough."



RESULTS: CONCERNS ABOUT USE OF BIO-SAMPLES

No participant at any visit reported concerns about long-term storage and future use of their hair or blood samples



CONCLUSIONS

- Finger-stick for DBS was acceptable to most patients and may be feasible in resource-limited settings
 - Hair samples were less acceptable than DBS, especially for regular and repeated collections
- Repeated exposure to procedures appeared to increase willingness and confidence for DBS sample collection by the patient her/himself at home
 - Further studies might examine the setting of sampling, and potential barriers to more widespread use in clinical practice
 - Research is needed to evaluate the ability of tenofovir DBS to measure ARV adherence



ACKNOWLEDGMENTS

HIV Center, NYSPI and Columbia University

Robert H. Remien, Ph.D. Patricia Warne, Ph.D. Reuben Robbins, Ph.D. Claude Ann Mellins, Ph.D. Javier Lopez-Rios, B.A. Cheng-Shiun Leu, Ph.D. Bruce Levin, Ph.D.

University of Cape Town

John Joska, M.B.Ch.B. Hetta Gouse, Ph.D. Michelle Henry Yoliswa Mtigeni

National Institute of Mental Health

Administrative Supplement to "Masivukeni: A Multimedia ART Adherence Intervention for Resource-Limited Settings (R01-MH95576-03S1; PI: Robert H. Remien, Ph.D.)

NIMH Program Officer: Michael Stirratt, Ph.D.

HIV Center for Clinical and Behavioral Studies (P30-MH43520; Center Director and PI: Robert H. Remien, Ph.D.)

